Donation & Investment Opportunities
Our Mission at StratisBioStratis Bio
At Stratis Bio, our goal is not only to provide relief for CRPS patients but also to advance research aimed at achieving full disease remission. Your donation supports both ongoing research and efforts to provide treatment for those who cannot afford it. In the future, we plan to establish a nonprofit organization focused on further supporting CRPS patients and others impacted by our products, such as those benefiting from our addiction relief formulation.
Investment Opportunities
Chronic pain affects millions, with the U.S. market valued at $30 billion and the global market at $80 billion, growing at 5-6% annually. Currently, no oral product exists that can effectively replace opioids like ours. In the U.S., there are an estimated 1.2 million CRPS sufferers, with 30-50% finding less than 50% pain relief. Our product provides over 50% pain relief for 60% of users, offering significant relief to those with partial relief from other treatments. The U.S. CRPS market is estimated at $300-$500 million, and our product has the potential to capture 20% of this market.
We are allowing investments with a goal of raising minimally $80,000. The vehicle is designed for conversion to a percentage of the value of the company at the time of conversion. The return on investment is capped at a 25 fold return.
The minimum investment is $500 and the maximum is $4,000. Each $500 gives the right to convert for 0.125% of the value of the company at the time of conversion.
As an example with a $4,000 investment
-
This gives the right to convert for 1% of the company value.
-
Company valued at $10 Million or an estimated 0.03% of the chronic pain market at the time of conversion would give a $100,000 return
-
For CRPS in general capturing 10% of the US market would give an estimated company valuation of $50 Million.
We are seeking investments to raise a minimum of $80,000. Investments will convert into a percentage of the company’s value at the time of conversion FINISH